Eventide Asset Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Eventide Asset Management’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-336,223	Closed	-$2.84M	–	149
2022 Q2	$2.84M	Hold	336,223	–	–	0.06%	129
2022 Q1	$4.58M	Hold	336,223	–	–	0.07%	124
2021 Q4	$6.61M	Sell	336,223 -263,777	-44%	-$6.21M	0.08%	126
2021 Q3	$19.3M	Hold	600,000	–	–	0.25%	97
2021 Q2	$20.3M	Hold	600,000	–	–	0.27%	93
2021 Q1	$22.5M	Hold	600,000	–	–	0.33%	88
2020 Q4	$19.9M	Buy	600,000 +150,000	+33%	+$6.08M	0.31%	91
2020 Q3	$16.5M	Hold	450,000	–	–	0.33%	85
2020 Q2	$14.8M	Hold	450,000	–	–	0.33%	80
2020 Q1	$11.6M	Hold	450,000	–	–	0.39%	78
2019 Q4	$14M	Buy	+450,000	New	+$11.3M	0.39%	69

Other funds holding PHAT

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Invesco Atlanta, Georgia $653B AUM 32.41% 1-Year Est. Return

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Ensign Peak Advisors

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

683 Capital Management New York $1.08B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return